CNPV
May 5, 2026

Commissioner's National Priority Voucher awarded to Bizengri (zenocutuzumab-zbco) for advanced unresectable or metastatic cholangiocarcinoma

Commissioner's National Priority Voucher awarded to Bizengri (zenocutuzumab-zbco) for advanced unresectable or metastatic cholangiocarcinoma. Partner Therapeutics announced on April 14th that they had already submitted the sBLA for this indication so a decision from the FDA is expected soon.

‍

Track every
FDA Priority Review Voucher Program.

Stay updated
Thank you!
Oops! Something went wrong while submitting your email.
HomeHistoryNewsCRL DashboardCNPV DashboardContactPRV Watch Pro
Privacy PolicyTerms and Conditions
Copyright © 2026 PRV Watch

This webpage has been compiled from manually reviewing thousands of documents from the U.S. Securities and Exchange Commission (SEC), U.S. Food and Drug Administrations (FDA), Federal Register, press releases and financial records. The information on this page has been compiled from publicly available sources only and does not include any undisclosed PRV issuance's, transactions or redemptions.

Stay in the loop

News, analysis, and insights from the world of Priority Review Vouchers.

Thank you!
Oops! Something went wrong while submitting your email.